Hopstem Biotechnology at 2024 CASSS CGPT Symposium

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA

The Site Initiation Visit (SIV) of the Phase 1 clinical trial on the indication of hemiplegia sequelae after chronic ischemic stroke with the hNPC01 universal cell therapy product of Hopstem Biotech was successfully held.